Skip to main content
NCBI home page
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2008:195–213. doi: 10.1007/978-1-59745-403-2_12

Nutrition and Polymyositis and Dermatomyositis

Ingela Loell, Ingrid Lundberg
Editor: Laura A Coleman1
PMCID: PMC7120298

Summary

• Chronic muscle inflammation in polymyositis or dermatomyositis causes muscle weakness and fatigue.

• The chronic inflammation could lead to a catabolic state and additional loss of muscle mass.

• The chronic muscle inflammation could induce a metabolic myopathy.

• Body weight may not be reliable to measure muscle loss, rather measurement of body composition is recommended.

•For patients with polymyositis or dermatomyositis it is important to provide the body with the right amount of macronutrients and trace elements for maintenance and improvement of body functions.

• One recommendation is supplementation with calcium and vitamin D.

• Another recommendation is regular physical exercise that during limited periods can be combined with supplements such as creatine, if done under the care of a physician.

Key Words: Creatine supplement, dermatomyositis, exercise, glutamine, inflammatory myopathies, polymyositis, vitamin D

References

  • 1.Hengstman G, van Venrooij W, Vencovsky J. The relative prevalence of dermatomyositis and polymyositis in Europe exhibits a latitudinal gradient. Ann Rheum Dis. 2000;59(2):141–142. doi: 10.1136/ard.59.2.141. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Okada S, et al. Global surface ultraviolet radiation intensity may modulate the clinical and immunologic expression of autoimmune muscle disease. Arthritis Rheum. 2003;48(8):2285–2293. doi: 10.1002/art.11090. [DOI] [PubMed] [Google Scholar]
  • 3.Love LA, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70(6):360–374. doi: 10.1097/00005792-199111000-00002. [DOI] [PubMed] [Google Scholar]
  • 4.Arnett FC, Targoff IN, Mimori T. Interrelationship of major histocompatibility complex class II alleles and autoantibodies in four ethnic groups with various forms of myositis. Arthritis Rheum. 1996;39(9):1507–1518. doi: 10.1002/art.1780390910. [DOI] [PubMed] [Google Scholar]
  • 5.Miller FW. Humoral immunity and immunogenetics in the idiopathic inflammatory myopathies. Curr Opin Rheumatol. 1991;3(6):902–910. doi: 10.1097/00002281-199112000-00002. [DOI] [PubMed] [Google Scholar]
  • 6.Authier FJ, Chariot P, Gherardi RK. Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART) Muscle Nerve. 2005;32(3):247–260. doi: 10.1002/mus.20338. [DOI] [PubMed] [Google Scholar]
  • 7.Reveille JD, Williams FM. Infection and musculoskeletal conditions: Rheumatologic complications of HIV infection. Best Pract Res Clin Rheumatol. 2006;20(6):1159–1179. doi: 10.1016/j.berh.2006.08.015. [DOI] [PubMed] [Google Scholar]
  • 8.Sheard C., Jr Dermatomyositis. AMA Arch Intern Med. 1951;88(5):640–658. doi: 10.1001/archinte.1951.03810110092009. [DOI] [PubMed] [Google Scholar]
  • 9.Logan RG, et al. Polymyositis: a clinical study. Ann Intern Med. 1966;65(5):996–1007. doi: 10.7326/0003-4819-65-5-996. [DOI] [PubMed] [Google Scholar]
  • 10.Pearson CM. Patterns of Polymyositis and Their Responses to Treatment. Ann Intern Med. 1963;59:827–838. doi: 10.7326/0003-4819-59-6-827. [DOI] [PubMed] [Google Scholar]
  • 11.Rose AL, Walton JN. Polymyositis: a survey of 89 cases with particular reference to treatment and prognosis. Brain. 1966;89(4):747–768. doi: 10.1093/brain/89.4.747. [DOI] [PubMed] [Google Scholar]
  • 12.Pearson CM, Bohan A. The spectrum of polymyositis and dermatomyositis. Med Clin North Am. 1977;61(2):439–457. doi: 10.1016/s0025-7125(16)31343-8. [DOI] [PubMed] [Google Scholar]
  • 13.Lundberg I, Brengman JM, Engel AG. Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls. J Neuroimmunol. 1995;63(1):9–16. doi: 10.1016/0165-5728(95)00122-0. [DOI] [PubMed] [Google Scholar]
  • 14.Lundberg I, et al. Cytokine production in muscle tissue of patients with idiopathic inflammatory myopathies. Arthritis Rheum. 1997;40(5):865–874. doi: 10.1002/art.1780400514. [DOI] [PubMed] [Google Scholar]
  • 15.De Bleecker JL, Meire VI, Declercq W. Immunolocalization of tumor necrosis factor-alpha and its receptors in inflammatory myopathies. Neuromuscul Disord. 1999;9(4):239–246. doi: 10.1016/S0960-8966(98)00126-6. [DOI] [PubMed] [Google Scholar]
  • 16.Nyberg P, et al. Increased expression of interleukin 1alpha and MHC class I in muscle tissue of patients with chronic, inactive polymyositis and dermatomyositis. J Rheumatol. 2000;27(4):940–948. [PubMed] [Google Scholar]
  • 17.Englund P, et al. Interleukin-1alpha expression in capillaries and major histocompatibility complex class I expression in type II muscle fibers from polymyositis and dermatomyositis patients: important pathogenic features independent of inflammatory cell clusters in muscle tissue. Arthritis Rheum. 2002;46(4):1044–1055. doi: 10.1002/art.10140. [DOI] [PubMed] [Google Scholar]
  • 18.Ulfgren A, et al. Down-regulation of the aberrant expression of the inflammation mediator high mobility group box chromosomal protein 1 in muscle tissue of patients with polymyositis and dermatomyositis treated with corticosteroids. Arthritis Rheum. 2004;50(5):1586–1594. doi: 10.1002/art.20220. [DOI] [PubMed] [Google Scholar]
  • 19.Figarella-Branger D, et al. Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies. Muscle Nerve. 2003;28(6):659–682. doi: 10.1002/mus.10462. [DOI] [PubMed] [Google Scholar]
  • 20.Spate U, Schulze PC. Proinflammatory cytokines and skeletal muscle. Curr Opin Clin Nutr Metab Care. 2004;7(3):265–269. doi: 10.1097/00075197-200405000-00005. [DOI] [PubMed] [Google Scholar]
  • 21.Murakami M, Kudo I. Recent advances in molecular biology and physiology of the prostaglandin E2-biosynthetic pathway. Prog Lipid Res. 2004;43(1):3–35. doi: 10.1016/S0163-7827(03)00037-7. [DOI] [PubMed] [Google Scholar]
  • 22.Tilley SL, Coffman TM, Koller BH. Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes. J Clin Invest. 2001;108(1):15–23. doi: 10.1172/JCI13416. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Harris SG, et al. Prostaglandins as modulators of immunity. Trends Immunol. 2002;23(3):144–150. doi: 10.1016/S1471-4906(01)02154-8. [DOI] [PubMed] [Google Scholar]
  • 24.Karamouzis M, et al. The response of muscle interstitial prostaglandin E(2)(PGE(2)), prostacyclin I(2)(PGI(2)) and thromboxane A(2)(TXA(2)) levels during incremental dynamic exercise in humans determined by in vivo microdialysis. Prostaglandins Leukot Essent Fatty Acids. 2001;64(4–5):259–263. doi: 10.1054/plef.2001.0269. [DOI] [PubMed] [Google Scholar]
  • 25.Kalliokoski KK, Ryberg LH, Scheede-Bergdahl AK, Doessing C, Kjaer A, Boushel R. Nitric oxide and prostaglandins influence local skeletal muscle blood flow during exercise in humans: coupling between local substrate uptake and blood flow. Am J Physiol Regul Integr Comp Physiol 2006(291): R803–R809. [DOI] [PubMed]
  • 26.Lundberg IE. The physiology of inflammatory myopathies: an overview. Acta Physiol Scand. 2001;171(3):207–213. doi: 10.1046/j.1365-201x.2001.00822.x. [DOI] [PubMed] [Google Scholar]
  • 27.Taylor PC, Sivakumar B. Hypoxia and angiogenesis in rheumatoid arthritis. Curr Opin Rhematol. 2005;17(3):293–298. doi: 10.1097/01.bor.0000155361.83990.5b. [DOI] [PubMed] [Google Scholar]
  • 28.Sultan SM, et al. Outcome in patients with idiopathic inflammatory myositis: morbidity and mortality. Rheumatology. 2002;41(1):22–26. doi: 10.1093/rheumatology/41.1.22. [DOI] [PubMed] [Google Scholar]
  • 29.Danko K, et al. Long-term survival of patients with idiopathic inflammatory myopathies according to clinical features: a longitudinal study of 162 cases. Medicine. 2004;83(1):35–42. doi: 10.1097/01.md.0000109755.65914.5e. [DOI] [PubMed] [Google Scholar]
  • 30.De Feo P, et al. Metabolic response to exercise. J Endocrinol Invest. 2003;26(9):851–854. doi: 10.1007/BF03345235. [DOI] [PubMed] [Google Scholar]
  • 31.Almawi WY, et al. Regulation of cytokine and cytokine receptor expression by glucocorticoids. J Leukoc Biol. 1996;60(5):563–572. doi: 10.1002/jlb.60.5.563. [DOI] [PubMed] [Google Scholar]
  • 32.Joyce DA, Gimblett G, Steer JH. Targets of glucocorticoid action on TNF-alpha release by macrophages. Inflamm Res. 2001;50(7):337–340. doi: 10.1007/PL00012387. [DOI] [PubMed] [Google Scholar]
  • 33.Barnes PJ. Corticosteroid effects on cell signalling. Eur Respir J. 2006;27(2):413–426. doi: 10.1183/09031936.06.00125404. [DOI] [PubMed] [Google Scholar]
  • 34.Ristimaki A, Narko K, Hla T. Down-regulation of cytokine-induced cyclo-oxygenase-2 transcript isoforms by dexamethasone: evidence for post-transcriptional regulation. Biochem J. 1996;318(Pt 1):325–331. doi: 10.1042/bj3180325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Hasselgren PO. Glucocorticoids and muscle catabolism. Curr Opin Clin Nutr Metab Care. 1999;2(3):201–205. doi: 10.1097/00075197-199905000-00002. [DOI] [PubMed] [Google Scholar]
  • 36.Horber FF, et al. Evidence that prednisone-induced myopathy is reversed by physical training. J Clin Endocrinol Metab. 1985;61(1):83–88. doi: 10.1210/jcem-61-1-83. [DOI] [PubMed] [Google Scholar]
  • 37.Horber FF, et al. Impact of physical training on the ultrastructure of midthigh muscle in normal subjects and in patients treated with glucocorticoids. J Clin Invest. 1987;79(4):1181–1190. doi: 10.1172/JCI112935. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Alexanderson H. Exercise: an important component of treatment in the idiopathic inflammatory myopathies. Curr Rheumatol Rep. 2005;7(2):115–124. doi: 10.1007/s11926-005-0063-2. [DOI] [PubMed] [Google Scholar]
  • 39.Alexanderson H, et al. The safety of a resistive home exercise program in patients with recent onset active polymyositis or dermatomyositis. Scand J Rheumatol. 2000;29(5):295–301. doi: 10.1080/030097400447679. [DOI] [PubMed] [Google Scholar]
  • 40.Ryder JW, Chibalin AV, Zierath JR. Intracellular mechanisms underlying increases in glucose uptake in response to insulin or exercise in skeletal muscle. Acta Physiol Scand. 2001;171(3):249–257. doi: 10.1046/j.1365-201x.2001.00827.x. [DOI] [PubMed] [Google Scholar]
  • 41.Christ-Roberts CY, Mandarino LJ. Glycogen synthase: key effect of exercise on insulin action. Exerc Sport Sci Rev. 2004;32(3):90–94. doi: 10.1097/00003677-200407000-00003. [DOI] [PubMed] [Google Scholar]
  • 42.Wojtaszewski JF, et al. Insulin signalling: effects of prior exercise. Acta Physiologica Scandinavica. 2003;178(4):321–8. doi: 10.1046/j.1365-201X.2003.01151.x. [DOI] [PubMed] [Google Scholar]
  • 43.Gustafsson T, et al. Exercise-induced expression of angiogenesis-related transcription and growth factors in human skeletal muscle.(see comment) Am J Physiol. 1999;276(2 Pt 2):H679–H685. doi: 10.1152/ajpheart.1999.276.2.H679. [DOI] [PubMed] [Google Scholar]
  • 44.Apor P, Radi A. [Vascular effects of physical activity] Orv Hetil. 2005;146(2):63–67. [PubMed] [Google Scholar]
  • 45.Prior BM, Yang HT, Terjung RL. What makes vessels grow with exercise training? J Appl Physiol. 2004;97(3):1119–1128. doi: 10.1152/japplphysiol.00035.2004. [DOI] [PubMed] [Google Scholar]
  • 46.Mills PJ, et al. Physical fitness attenuates leukocyte–endothelial adhesion in response to acute exercise. J Appl Physiol. 2006;101(3):785–788. doi: 10.1152/japplphysiol.00135.2006. [DOI] [PubMed] [Google Scholar]
  • 47.Petersen AM, Pedersen BK. The anti-inflammatory effect of exercise. J Appl Physiol. 2005;98(4):1154–1162. doi: 10.1152/japplphysiol.00164.2004. [DOI] [PubMed] [Google Scholar]
  • 48.Hargreaves M, Cameron-Smith D. Exercise, diet, and skeletal muscle gene expression. Med Sci Sports Exerc. 2002;34(9):1505–1508. doi: 10.1097/00005768-200209000-00017. [DOI] [PubMed] [Google Scholar]
  • 49.Yarasheski KE. Exercise, aging, and muscle protein metabolism. J Gerontol A Biol Sci Med Sci. 2003;58(10):M918–M922. doi: 10.1093/gerona/58.10.m918. [DOI] [PubMed] [Google Scholar]
  • 50.Blair SN, et al. How much physical activity is good for health? Annu Rev Public Health. 1992;13:99–126. doi: 10.1146/annurev.pu.13.050192.000531. [DOI] [PubMed] [Google Scholar]
  • 51.Alexanderson H, Stenstrom CH, Lundberg I. Safety of a home exercise programme in patients with polymyositis and dermatomyositis: a pilot study. Rheumatology. 1999;38(7):608–611. doi: 10.1093/rheumatology/38.7.608. [DOI] [PubMed] [Google Scholar]
  • 52.Rennie MJ, Tipton KD. Protein and amino acid metabolism during and after exercise and the effects of nutrition. Annu Rev Nutr. 2000;20:457–483. doi: 10.1146/annurev.nutr.20.1.457. [DOI] [PubMed] [Google Scholar]
  • 53.Levenhagen DK, et al. Postexercise nutrient intake timing in humans is critical to recovery of leg glucose and protein homeostasis. Am J Physiol Endocrinol Metab. 2001;280(6):E982–E993. doi: 10.1152/ajpendo.2001.280.6.E982. [DOI] [PubMed] [Google Scholar]
  • 54.Wilborn CD, Willoughby DS. The role of dietary protein intake and resistance training on myosin heavy chain expression. J Int Soc Sports Nutr. 2004;1(2):27–34. doi: 10.1186/1550-2783-1-2-27. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55.Becker W, et al. Nordic nutrition recommendations. Ugeskrift for Laeger. 2006;168(1):76–77. [PubMed] [Google Scholar]
  • 56.Gendek EG, Kedziora J, Gendek-Kubiak H. Can tissue transglutaminase be a marker of idiopathic inflammatory myopathies? Immunol Lett. 2005;97(2):245–249. doi: 10.1016/j.imlet.2004.11.017. [DOI] [PubMed] [Google Scholar]
  • 57.Facchiano F, Facchiano A, Facchiano AM. The role of transglutaminase-2 and its substrates in human diseases. Front Biosci. 2006;11:1758–1773. doi: 10.2741/1921. [DOI] [PubMed] [Google Scholar]
  • 58.Kim SY. New target against inflammatory diseases: transglutaminase 2. Arch Immunol Ther Exp (Warsz) 2004;52(5):332–337. [PubMed] [Google Scholar]
  • 59.Selva-O’callaghan A, et al. Celiac disease and antibodies associated with celiac disease in patients with inflammatory myopathy. Muscle Nerve 2006;11. [DOI] [PubMed]
  • 60.Lombardo JA. Supplements and athletes. South Med J. 2004;97(9):877–879. doi: 10.1097/01.SMJ.0000140113.77376.14. [DOI] [PubMed] [Google Scholar]
  • 61.Demant TW, Rhodes EC. Effects of creatine supplementation on exercise performance. Sports Med. 1999;28(1):49–60. doi: 10.2165/00007256-199928010-00005. [DOI] [PubMed] [Google Scholar]
  • 62.Williams MH, Branch JD. Creatine supplementation and exercise performance: an update.(see comment) J Am Coll Nutr. 1998;17(3):216–234. doi: 10.1080/07315724.1998.10718751. [DOI] [PubMed] [Google Scholar]
  • 63.Mesa JL, et al. Oral creatine supplementation and skeletal muscle metabolism in physical exercise. Sports Med. 2002;32(14):903–944. doi: 10.2165/00007256-200232140-00003. [DOI] [PubMed] [Google Scholar]
  • 64.Kreider RB. Effects of creatine supplementation on performance and training adaptations. Mol Cell Biochem. 2003;244(1–2):89–94. [PubMed] [Google Scholar]
  • 65.Volek JS, Rawson ES. Scientific basis and practical aspects of creatine supplementation for athletes. Nutrition. 2004;20(7–8):609–614. doi: 10.1016/j.nut.2004.04.014. [DOI] [PubMed] [Google Scholar]
  • 66.Park JH, et al. Use of magnetic resonance imaging and P-31 magnetic resonance spectroscopy to detect and quantify muscle dysfunction in the amyopathic and myopathic variants of dermatomyositis. Arthritis Rheum. 1995;38(1):68–77. doi: 10.1002/art.1780380111. [DOI] [PubMed] [Google Scholar]
  • 67.Park JH, Ryder VT, Hernanz-Schulman NM, Partain M, Price RR, Olsen NJ., Park JH, Vital TL, Ryder NM, Hernanz-Schulman M, Partain CL, Price RR, Olsen NJ. Magnetic resonance imaging and P-31 magnetic resonance spectroscopy provide unique quantitative data useful in the longitudinal management of patients with dermatomyositis. Arthritis Rheum. 1994;37(5):736–746. doi: 10.1002/art.1780370519. [DOI] [PubMed] [Google Scholar]
  • 68.Chung Y-L, Pipitone AH, MOrrison N. Creatine supplements in patients with idiopathic inflammatory myopathies who are clinically weak after conventional pharmacologic treatment: Six-month, double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2007;15(57(4):694–702. doi: 10.1002/art.22687. [DOI] [PubMed] [Google Scholar]
  • 69.Wyss M, Kaddurah-Daouk R. Creatine and creatinine metabolism. Physiol Rev. 2000;80(3):1107–1213. doi: 10.1152/physrev.2000.80.3.1107. [DOI] [PubMed] [Google Scholar]
  • 70.Chung Y-L,Pipitone AH, MorrisonN, et al. Creatine supplements improve muscle function in idiopathic inflammatory myopathies in a 6-month double blind, randomized placebo-controlled study. Arthritis Care Res 2006. [DOI] [PubMed]
  • 71.Nomura A, et al. Anti-inflammatory activity of creatine supplementation in endothelial cells in vitro. Br J Pharmacol. 2003;139(4):715–720. doi: 10.1038/sj.bjp.0705316. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 72.DesJardins M. Supplement use in the adolescent athlete. Curr Sports Med Rep. 2002;1(6):369–373. doi: 10.1007/s11932-002-0050-6. [DOI] [PubMed] [Google Scholar]
  • 73.Escolar DM, et al. CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy. Ann Neurol. 2005;58(1):151–155. doi: 10.1002/ana.20523. [DOI] [PubMed] [Google Scholar]
  • 74.Hartgens F Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34(8):513–554. doi: 10.2165/00007256-200434080-00003. [DOI] [PubMed] [Google Scholar]
  • 75.Eenoo P, Delbeke FT. Metabolism and excretion of anabolic steroids in doping control–new steroids and new insights. J Steroid Biochem Mol Biol. 2006;101(4–5):161–178. doi: 10.1016/j.jsbmb.2006.06.024. [DOI] [PubMed] [Google Scholar]
  • 76.Sheffield-Moore M, et al. Short-term oxandrolone administration stimulates net muscle protein synthesis in young men. J Clin Endocrinol Metab. 1999;84(8):2705–2711. doi: 10.1210/jc.84.8.2705. [DOI] [PubMed] [Google Scholar]
  • 77.Rutkove SB, et al. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology. 2002;58(7):1081–1087. doi: 10.1212/wnl.58.7.1081. [DOI] [PubMed] [Google Scholar]
  • 78.Fenichel GM, et al. A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology. 2001;56(8):1075–1079. doi: 10.1212/wnl.56.8.1075. [DOI] [PubMed] [Google Scholar]
  • 79.Creutzberg EC, et al. A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest. 2003;124(5):1733–1742. doi: 10.1378/chest.124.5.1733. [DOI] [PubMed] [Google Scholar]
  • 80.Newsholme EA, Calder PC. The proposed role of glutamine in some cells of the immune system and speculative consequences for the whole animal. Nutrition. 1997;13(7–8):728–730. doi: 10.1016/s0899-9007(97)83034-1. [DOI] [PubMed] [Google Scholar]
  • 81.Biolo G, et al. Muscle glutamine depletion in the intensive care unit. Int J Biochem Cell Biol. 2005;37(10):2169–2179. doi: 10.1016/j.biocel.2005.05.001. [DOI] [PubMed] [Google Scholar]
  • 82.Burnham EL, Moss M, Ziegler TR. Myopathies in critical illness: characterization and nutritional aspects. J Nutr. 2005;135(7):1818S–1823S. doi: 10.1093/jn/135.7.1818S. [DOI] [PubMed] [Google Scholar]
  • 83.Singleton KD, Beckey VE, Wischmeyer PE. Glutamine prevents activation of NF-kappaB and stress kinase pathways, attenuates inflammatory cytokine release, and prevents acute respiratory distress syndrome (ARDS) following sepsis. Shock. 2005;24(6):583–589. doi: 10.1097/01.shk.0000185795.96964.71. [DOI] [PubMed] [Google Scholar]
  • 84.Burnham EL, Moss M, Ziegler TR. Myopathies in critical illness: characterization and nutritional aspects. J Nutr. 2005;135(7):1818S–1823S. doi: 10.1093/jn/135.7.1818S. [DOI] [PubMed] [Google Scholar]
  • 85.Mok E, et al. Oral glutamine and amino acid supplementation inhibit whole-body protein degradation in children with Duchenne muscular dystrophy. Am J Clin Nutr. 2006;83(4):823–828. doi: 10.1093/ajcn/83.4.823. [DOI] [PubMed] [Google Scholar]
  • 86.DeFilippisAP, Sperling LS. Understanding omega-3‘s. Am Heart J. 2006;151(3):564–570. doi: 10.1016/j.ahj.2005.03.051. [DOI] [PubMed] [Google Scholar]
  • 87.Doshi M, et al. Effect of dietary enrichment with n-3 polyunsaturated fatty acids (PUFA) or n-9 PUFA on arachidonate metabolism in vivo and experimentally induced inflammation in mice. Biol Pharm Bull. 2004;27(3):319–323. doi: 10.1248/bpb.27.319. [DOI] [PubMed] [Google Scholar]
  • 88.Kelley VE, et al. A fish oil diet rich in eicosapentaenoic acid reduces cyclooxygenase metabolites, and suppresses lupus in MRL-lpr mice. J Immunol. 1985;134(3):1914–1919. [PubMed] [Google Scholar]
  • 89.Arterburn LM, Hall EB, Oken H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am J Clin Nutr. 2006;83(6 suppl):1467S–1476S. doi: 10.1093/ajcn/83.6.1467S. [DOI] [PubMed] [Google Scholar]
  • 90.Simopoulos AP. Essential fatty acids in health and chronic diseases. Forum Nutr. 2003;56:67–70. [PubMed] [Google Scholar]
  • 91.Calder PC. n-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr. 2006;83(6 suppl):1505S–1519S. doi: 10.1093/ajcn/83.6.1505S. [DOI] [PubMed] [Google Scholar]
  • 92.Pennisi P, Trombetti A, Rizzoli R. Glucocorticoid-induced osteoporosis and its treatment. Clin Orthop Relat Res. 2006;443:39–47. doi: 10.1097/01.blo.0000200238.29931.1f. [DOI] [PubMed] [Google Scholar]
  • 93.Cantorna MT, et al. Vitamin D status, 1,25-dihydroxyvitamin D3, and the immune system. Am J Clin Nutr. 2004;80(6 suppl):1717S–20S. doi: 10.1093/ajcn/80.6.1717S. [DOI] [PubMed] [Google Scholar]
  • 94.Alsufyani KA, et al. Bone mineral density in children and adolescents with systemic lupus erythematosus, juvenile dermatomyositis, and systemic vasculitis: relationship to disease duration, cumulative corticosteroid dose, calcium intake, and exercise. J Rheumatol. 2005;32(4):729–733. [PubMed] [Google Scholar]
  • 95.Cantorna MT, Mahon BD. D-hormone and the immune system. J Rheumatol Suppl. 2005;76:11–20. [PubMed] [Google Scholar]
  • 96.Zittermann A, Vitamin D. in preventive medicine: are we ignoring the evidence? Br J Nutr. 2003;89(5):552–572. doi: 10.1079/BJN2003837. [DOI] [PubMed] [Google Scholar]
  • 97.CantornaMT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med (Maywood) 2004;229(11):1136–1142. doi: 10.1177/153537020422901108. [DOI] [PubMed] [Google Scholar]
  • 98.Larsson P, et al. A vitamin D analogue (MC 1288) has immunomodulatory properties and suppresses collagen-induced arthritis (CIA) without causing hypercalcaemia. Clin Exp Immunol. 1998;114(2):2772–83. doi: 10.1046/j.1365-2249.1998.00706.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 99.Adorini L. Intervention in autoimmunity: the potential of vitamin D receptor agonists. Cell Immunol. 2005;233(2):115–124. doi: 10.1016/j.cellimm.2005.04.013. [DOI] [PubMed] [Google Scholar]
  • 100.Grant WB, Holick MF. Benefits and requirements of vitamin D for optimal health: a review. Altern Med Rev. 2005;10(2):94–111. [PubMed] [Google Scholar]
  • 101.Schneider C. Chemistry and biology of vitamin E. Mol Nutr Fod Res. 2005;49(1):7–30. doi: 10.1002/mnfr.200400049. [DOI] [PubMed] [Google Scholar]
  • 102.Traber MG, Sies H. Vitamin E in humans: demand and delivery. Annu Rev Nutr. 1996;16:321–347. doi: 10.1146/annurev.nu.16.070196.001541. [DOI] [PubMed] [Google Scholar]
  • 103.Tomasi LG. Reversibility of human myopathy caused by vitamin E deficiency. Neurology. 1979;29(8):1182–1186. doi: 10.1212/wnl.29.8.1182. [DOI] [PubMed] [Google Scholar]
  • 104.Osoegawa M, et al. [A patient with vitamin E deficient, myopathy presenting with amyotrophy] Rinsho Shinkeigaku. 2001;41(7):428–431. [PubMed] [Google Scholar]
  • 105.Schneider C. Chemistry and biology of vitamin E. Mol Nutr Food Res. 2005;49(1):7–30. doi: 10.1002/mnfr.200400049. [DOI] [PubMed] [Google Scholar]
  • 106.Sacheck JM, Blumberg JB. Role of vitamin E and oxidative stress in exercise. Nutrition. 2001;17(10):809–814. doi: 10.1016/S0899-9007(01)00639-6. [DOI] [PubMed] [Google Scholar]
  • 107.Jackson MJ, et al. Vitamin E and the oxidative stress of exercise. Ann N Y Acad Sci. 2004;1031:158–168. doi: 10.1196/annals.1331.015. [DOI] [PubMed] [Google Scholar]
  • 108.Beaton LJ, et al. Contraction-induced muscle damage is unaffected by vitamin E supplementation. Med Sci Sports Exerc. 2002;34(5):798–805. doi: 10.1097/00005768-200205000-00012. [DOI] [PubMed] [Google Scholar]
  • 109.Haas DC. Vitamin E therapy in polymyositis. South Med J. 1977;70(9):1148–1149. [PubMed] [Google Scholar]
  • 110.Manach C, et al. Polyphenols: food sources and bioavailability. Am J ClinNutr. 2004;79(5):727–747. doi: 10.1093/ajcn/79.5.727. [DOI] [PubMed] [Google Scholar]
  • 111.Nam NH. Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem. 2006;6(8):945–951. doi: 10.2174/138955706777934937. [DOI] [PubMed] [Google Scholar]
  • 113.Dorchies OM, et al. Green tea extract and its major polyphenol (-)-epigallocatechin gallate improve muscle function in a mouse model for Duchenne muscular dystrophy. Am J Physiol Cell Physiol. 2006;290(2):C616–C625. doi: 10.1152/ajpcell.00425.2005. [DOI] [PubMed] [Google Scholar]
  • 113.Moon Y, Lee M, Yang H. Involvement of early growth response gene 1 in the modulation of microsomal prostaglandin E synthase 1 by epigallocatechin gallate in A549 human pulmonary epithelial cells. Biochem Pharmacol. 2007;73(1):125–135. doi: 10.1016/j.bcp.2006.08.017. [DOI] [PubMed] [Google Scholar]
  • 114.Pugh N, et al. Isolation of three high molecular weight polysaccharide preparations with potent immunostimulatory activity from Spirulina platensis, aphanizomenon flos-aquae and Chlorella pyrenoidosa. Planta Med. 2001;67(8):737–742. doi: 10.1055/s-2001-18358. [DOI] [PubMed] [Google Scholar]
  • 115.Lee AN, Werth VP. Activation of autoimmunity following use of immunostimulatory herbal supplements. Arch Dermatol. 2004;140(6):723–727. doi: 10.1001/archderm.140.6.723. [DOI] [PubMed] [Google Scholar]

Articles from Nutrition and Rheumatic Disease are provided here courtesy of Nature Publishing Group

RESOURCES